Suppr超能文献

基于作用模式的受体介导毒性分析:以过氧化物酶体增殖物激活受体α(PPARα)为例。

Mode of action framework analysis for receptor-mediated toxicity: The peroxisome proliferator-activated receptor alpha (PPARα) as a case study.

机构信息

US Environmental Protection Agency , Research Triangle Park, NC , USA .

出版信息

Crit Rev Toxicol. 2014 Jan;44(1):1-49. doi: 10.3109/10408444.2013.835784. Epub 2013 Nov 4.

Abstract

Several therapeutic agents and industrial chemicals induce liver tumors in rodents through the activation of the peroxisome proliferator-activated receptor alpha (PPARα). The cellular and molecular events by which PPARα activators induce rodent hepatocarcinogenesis has been extensively studied and elucidated. This review summarizes the weight of evidence relevant to the hypothesized mode of action (MOA) for PPARα activator-induced rodent hepatocarcinogenesis and identifies gaps in our knowledge of this MOA. Chemical-specific and mechanistic data support concordance of temporal and dose-response relationships for the key events associated with many PPARα activators including a phthalate ester plasticizer di(2-ethylhexyl) phthalate (DEHP) and the drug gemfibrozil. While biologically plausible in humans, the hypothesized key events in the rodent MOA, for PPARα activators, are unlikely to induce liver tumors in humans because of toxicodynamic and biological differences in responses. This conclusion is based on minimal or no effects observed on growth pathways, hepatocellular proliferation and liver tumors in humans and/or species (including hamsters, guinea pigs and cynomolgous monkeys) that are more appropriate human surrogates than mice and rats at overlapping dose levels. Overall, the panel concluded that significant quantitative differences in PPARα activator-induced effects related to liver cancer formation exist between rodents and humans. On the basis of these quantitative differences, most of the workgroup felt that the rodent MOA is "not relevant to humans" with the remaining members concluding that the MOA is "unlikely to be relevant to humans". The two groups differed in their level of confidence based on perceived limitations of the quantitative and mechanistic knowledge of the species differences, which for some panel members strongly supports but cannot preclude the absence of effects under unlikely exposure scenarios.

摘要

几种治疗药物和工业化学物质通过激活过氧化物酶体增殖物激活受体α(PPARα)在啮齿动物中诱导肝肿瘤。PPARα 激活剂诱导啮齿动物肝癌发生的细胞和分子事件已被广泛研究和阐明。本综述总结了与 PPARα 激活剂诱导的啮齿动物肝癌发生的假设作用模式(MOA)相关的证据权重,并确定了我们对该 MOA 认识的空白。化学特异性和机制数据支持许多 PPARα 激活剂相关关键事件的时间和剂量-反应关系的一致性,包括邻苯二甲酸酯类增塑剂邻苯二甲酸二(2-乙基己基)酯(DEHP)和药物吉非贝齐。虽然在人类中具有生物学意义,但啮齿动物 MOA 中假设的关键事件不太可能导致人类肝肿瘤,因为在毒性动力学和生物学反应方面存在差异。这一结论基于在人类中观察到的生长途径、肝细胞增殖和肝肿瘤的最小或无影响,以及在重叠剂量水平下比小鼠和大鼠更适合作为人类替代物的物种(包括仓鼠、豚鼠和食蟹猴)。总体而言,专家组得出结论,PPARα 激活剂诱导的与肝癌形成相关的效应在啮齿动物和人类之间存在显著的定量差异。基于这些定量差异,大多数工作组认为啮齿动物 MOA“与人类无关”,其余成员则认为 MOA“不太可能与人类有关”。这两个小组在置信水平上存在差异,这是基于对物种差异的定量和机制知识的局限性的看法,对于一些小组成员来说,这些差异强烈支持但不能排除在不太可能的暴露情况下缺乏影响的可能性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验